Correct coding is the responsibility of the provider submitting a claim for the item or service. Here we provide general billing and coding information for BANZEL® and related services. Please check with the payor to verify coding or special billing requirements.
NDCs help providers and payors identify specific product package sizes. The BANZEL® NDCs are listed below.
BANZEL® Package Size |
NDC |
BANZEL® 200 mg tablets |
62856-582-52 |
BANZEL® 400 mg tablets |
62856-583-52 |
BANZEL® Oral Suspension |
62856-584-46 |
Some payors require providers to report 11-digit NDCs when reporting a drug on a claim form. Converting the 10-digit NDC for BANZEL® to an 11-digit NDC requires the use of a leading zero in the product code section of the NDC (i.e., the middle section). Below is one example of how to report using the 11-digit NDC.
10-Digit NDC Example |
11-Digit NDC Example with Leading Zero |
AAAAA-BBB-CC |
AAAAA-0BBB-CC |
BANZEL® 10-Digit NDC |
BANZEL® 11-Digit NDC with Leading Zero |
62856-582-52 |
62856-0582-52 |
ICD diagnosis codes help providers and payors proceed with the benefit investigation and prior authorization process, if required.
The ICD-10 codes that may be applicable for BANZEL® use are listed below.
ICD-10 Diagnosis Code |
Description |
G40.811 |
Lennox-Gastaut syndrome, not intractable, with status epilepticus |
G40.812 |
Lennox-Gastaut syndrome, not intractable, without status epilepticus |
G40.801 |
Other epilepsy, not intractable, with status epilepticus |
G40.802 |
Other epilepsy, not intractable, without status epilepticus |
G40.803 |
Other epilepsy, intractable, with status epilepticus |
G40.804 |
Other epilepsy, intractable, without status epilepticus |
G40.901 |
Epilepsy, unspecified, not intractable, with status epilepticus |
G40.909 |
Epilepsy, unspecified, not intractable, without status epilepticus |
G40.911 |
Epilepsy, unspecified, intractable, with status epilepticus |
G40.919 |
Epilepsy, unspecified, intractable, without status epilepticus |
Eisai cannot guarantee payment of any claim. Coding, coverage, and reimbursement may vary significantly by payor, plan, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payors following the receipt of claims. For additional information, customers should consult with their payors for all relevant coding, reimbursement, and coverage requirements. It is the sole responsibility of the provider to select the proper code and ensure the accuracy of all claims used in seeking reimbursement. All services must be medically appropriate and properly supported in the patient medical record.
BANZEL is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in pediatric patients 1 year of age and older, and in adults.
For more information about BANZEL® please see Prescribing Information.
BANZEL® is available by prescription only.
Phone number - 1-855-EISAI-4-U (1-855-347-2448)
Monday - Friday, 9 am to 5 pm ET
This information is intended for use by our healthcare professionals in the United States only. Eisai Inc. recognizes the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here is not appropriate for use outside the United States.
This site contains information about products that may have different product labeling in different countries. This site is published by Eisai Inc.
BANZ-US2338